What's in Fatma Zehra Arvas's pipeline?

Fatma Zehra Arvas has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Fatma Zehra Arvas's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fatma-zehra-arvas.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Fatma Zehra Arvas — Portfolio Competitive Intelligence Brief

Fatma Zehra Arvas pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Amoxicillin-Clarithromycin-Lansoprazole	Amoxicillin-Clarithromycin-Lansoprazole	marketed	Triple therapy antibiotic combination with proton pump inhibitor	Helicobacter pylori bacterial ribosomes (amoxicillin and clarithromycin); H+/K+-ATPase (lansoprazole)	Gastroenterology

Therapeutic area mix

Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Fatma Zehra Arvas:

Cite this brief

Drug Landscape (2026). Fatma Zehra Arvas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fatma-zehra-arvas. Accessed 2026-05-16.